胶质母细胞瘤放疗中自适应与固定推量计划的前瞻性比较
前瞻性评估61例接受自适应放疗的胶质母细胞瘤患者,比较固定与自适应推量计划对放疗后MRI所示推量靶区的覆盖与适形性。自适应计划推量靶区V95中位数98.3%高于固定计划95.6%(P<0.01);全切除患者适形指数固定计划1.61 vs 自适应计划1.48(P=0.01)。
要点
- 自适应推量计划推量靶区V95中位数98.3%,固定计划95.6%(P<0.01)。
- 非全切除患者V95中位数自适应98.2% vs 固定91.9%(P<0.01)。
- 全切除患者适形指数固定1.61 vs 自适应1.48(P=0.01)。
核心结论
- 胶质母细胞瘤自适应放疗改善了靶区覆盖并降低了正常脑组织剂量。
- 按切除程度分析,全切除患者可预期正常脑剂量降低,部分切除或活检患者可预期覆盖增加。
研究设计与样本
- 前瞻性评估61例接受自适应放疗的胶质母细胞瘤患者。
- 初程临床靶区为术后MRI(放疗前MRI)T2高信号加10 mm,计划靶区为临床靶区加5 mm,处方40 Gy。
- 放疗中行MRI及第二次计划CT,基于放疗前MRI和放疗中MRI分别创建推量临床靶区(切除腔及增强T1加权MRI残余肿瘤加10 mm)。
- 推量计划靶区为推量临床靶区加5 mm,分别基于第一次和第二次计划CT创建固定与自适应推量计划,处方20 Gy。
- 基于放疗后MRI创建推量计划靶区,比较固定与自适应推量计划中该靶区的剂量体积直方图及适形指数。
主要发现
- 固定与自适应推量计划对放疗后MRI推量靶区的V95中位数分别为95.6%和98.3%(P<0.01)。
- 全切除患者V95中位数固定计划97.4% vs 自适应计划98.8%(P=0.41)。
- 非全切除患者V95中位数固定计划91.9% vs 自适应计划98.2%(P<0.01)。
- 全部患者适形指数中位数固定计划1.45 vs 自适应计划1.47(P=0.31)。
- 全切除患者适形指数中位数固定计划1.61 vs 自适应计划1.48(P=0.01);非全切除患者固定计划1.36 vs 自适应计划1.44(P=0.13)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To analyze the efficacy of adaptive radiotherapy (ART) for glioblastoma. METHODS: Sixty-one glioblastoma patients who received ART were prospectively evaluated. The initial clinical target volume (CTVinitial) was represented by T2 hyperintensity on postoperative MRIs (pre-RT MRI [MRIpre])plus 10 mm. The initial planning target volume (PTVinitial) was the CTVinitial plus a 5-mm margin. The PTVinitial received 40 Gy. An MRI and a second planning CT were performed during radiotherapy (MRImid). Two types of boost CTVs (the resection cavity and residual tumor on enhanced T1-weighted MRI plus 10 mm) were created based on the MRIpre and MRImid (CTVboost-pre and -mid). The boost PTV (PTVboost) was the CTVboost plus 5 mm. Two types of boost plans (fixed and adaptive boost plans in the first and second planning CT, respectively) of 20 Gy were created. The PTV based on the post-RT MRI (PTVboost-post) was created, and the dose-volume histograms of the PTVboost-post in the fixed and adaptive boost plans were compared. Additionally, the conformity indices (CIs) of the fixed and adaptive boost plans were compared. RESULTS: The median V95 of the PTVboost-post of the fixed and adaptive boost plans (V95pre and V95mid) were 95.6% and 98.3%, respectively (P < 0.01). The median V95pre and V95mid of patients after gross total resection (GTR) were 97.4% and 98.8%, respectively (P = 0.41); in contrast, the median values of patients after non-GTR were 91.9% and 98.2%, respectively (P < 0.01). The median CIs of the fixed and adaptive boost plans in all patients were 1.45 and 1.47, respectively (P = 0.31). The median CIs of the fixed and adaptive boost plans in patients after GTR were 1.61 and 1.48, respectively (P = 0.01); in contrast, those in patients after non-GTR were 1.36 and 1.44, respectively (P = 0.13). CONCLUSION: ART for glioblastoma improved the target coverage and dose reduction for the normal brain. By analyzing the results according to the resection rate, we can expect a decrease in normal brain dose in patients with GTR and an increase in coverage in those with partial resection or biopsy.
引用
- Matsuyama T, Fukugawa Y, Kuroda J, et al. A prospective comparison of adaptive and fixed boost plans in radiotherapy for glioblastoma. Radiat Oncol. 2022. PMID: 35193635. doi:10.1186/s13014-022-02007-4
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。